Exelixis of San Francisco said it licensed genetic technology to enable advanced analysis in the laboratory mouse.
The licensed technology, which was originally developed by William Dove of the Wisconsin Alumni Research Foundation, elucidates gene function and will possibly allow Exelixis to identify key disease genes or drug targets that would be difficult to identify with alternative mouse technologies, the company said.
Using the technology, a researcher can assign a gene to a particular biochemical or disease-related signaling pathway and establish the consequence of modifying its activity with respect to a desired therapeutic outcome, Exelixis said.